UBS analyst Michael Yee reiterated a Buy rating on AnaptysBio today and set a price target of $90.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Yee has given his Buy rating due to a combination of factors related to both AnaptysBio’s royalty stream and its development pipeline. He has increased his price target to $90 per share, attributing roughly half of this value to the durable royalty income from Jemperli and the other half to the potential of the spun-out biopharma entity, TRAX, where he sees especially attractive risk‑reward.
On the royalty side, he highlights that Jemperli could outperform current consensus peak sales forecasts, supported by multiple ongoing GSK trials in new tumor settings where existing competitors are weaker or absent. On the pipeline side, he emphasizes upcoming Phase 1B data for ANB033 in celiac disease, viewing positive results—particularly on mucosal protection and healing endpoints—as a key catalyst that could transform TRAX into a major value driver and unlock substantial upside for shareholders.
In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $73.00 price target.